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ABSTRACT (word count 212) 
Introduction 
Gastrointestinal infections (GII) can cause serious ill-health and morbidity. Although 
primarily transmitted through faecal contamination of food or water, transmission 
through sexual activity is well-described, especially among men who have sex with 
men (MSM).   
Methods 
We investigated the prevalence of GIIs among a convenience sample of MSM who 
were consecutively diagnosed with rectal Chlamydia trachomatis (CT) at 12 UK 
genitourinary medicine clinics during 10 weeks in 2012. Residual rectal swabs were 
coded, anonymised and tested for Shigella, Campylobacter, Salmonella, shiga toxin-
producing Escherichia coli (STEC) and enteroaggregative E. coli (EAEC) using a 
real-time PCR. Results were linked to respective coded and anonymised clinical and 
demographic data. Associations were investigated using Fisher’s Exact tests.    
Results 
Of 444 specimens tested, overall GII prevalence was 8.6%[95% CI 6.3%-11.6%]: 
1.8% [0.9%-3.6%] tested positive for Shigella, 1.8%[0.9%-3.6%] for Campylobacter 
and 5.2%[3.5%-7.7%] for EAEC. No specimens tested positive for Salmonella or 
other diarrhoeagenic E. coli pathotypes.  Among those with any GII, 14/30 were 
asymptomatic (2/7 with Shigella, 3/6 with Campylobacter, and 9/17 with EAEC). 
Shigella prevalence was higher in MSM who were HIV-positive (4.7%[2.1%-10.2%] 
versus 0.5%[0.1%-3.2%] in HIV-negative MSM; p=0.01).  
Conclusions 
In this small feasibility study, MSM with rectal CT appeared to be at appreciable risk 
of GII. Asymptomatic carriage may play a role in sexual transmission of GII.  
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KEY MESSAGES 
 About 9% of men who have sex with men with rectal chlamydia were co-
infected with a gastrointestinal infection (GII); 13% if they were HIV-positive 
 Among those with GII, 14 of 30 were asymptomatic suggesting asymptomatic 
carriage may play a role in sexual transmission of GII 
 Testing rectal swabs may be a feasible and acceptable method for detecting 
GIIs  
 
 
INTRODUCTION 
Gastrointestinal infections (GII) can cause serious ill-health and morbidity, including 
diarrhoea, dehydration, bacteraemia, Reiter’s syndrome and haemolytic uraemic 
syndrome (HUS). Transmission occurs through the faecal-oral route and is primarily 
associated with contaminated food or water. Sexual transmission is well-described, 
especially among men who have sex with men (MSM) among whom it is usually 
associated with exposure through direct or indirect oro-anal contact.[1-5]  
In the last decade there have been remarkable changes in the epidemiology of some 
GII in England.[4,6,7] Diagnoses of non-travel associated Shigella flexneri, usually 
associated with travel to endemic areas, have risen sharply; non-travel associated 
cases now out-number travel-associated cases.[6] Control measures have focussed 
on raising awareness amongst clinicians and patients to reduce spread in those with 
symptoms. However, these have made little impact on the Shigella spp. 
epidemics.[6] It is unclear whether asymptomatic infection, which is an important 
characteristic for many sexually transmitted infections (STIs), plays a role in sexual 
transmission of GII.  
The prevalence, incidence and transmission dynamics of GII in MSM is poorly 
understood because (i) surveillance data reflect the subset with acute infection 
presenting to clinical services, (ii) sexual exposure is not routinely recorded for GII, 
and (iii) there is no simple method for routinely screening MSM for GII. We used a 
convenience sample of MSM diagnosed with rectal Chlamydia trachomatis (CT) at 
selected UK sexual health clinics to investigate whether rectal swabs from routine 
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STI screens would make suitable specimens for GII testing and to provide crude 
estimates of GII prevalence in these men. Infection with rectal chlamydia suggests a 
history of receptive condomless anal intercourse and identifies a group potentially at 
higher risk of GII from indirect oro-anal contact. As such, MSM with rectal CT are an 
appropriate population for a feasibility study on GII. 
 
METHODS 
Study population and study period 
We used a convenience sample of MSM from a Lymphogranuloma venereum (LGV) 
case-finding study.[8]  The LGV study included only MSM who had been 
consecutively diagnosed with rectal CT at 12 clinics in the UK (in Brighton, Glasgow, 
London and Manchester) between 24th September and 7th December 2012 except 
those who had taken any antibiotics during the previous 6 weeks.[8] The recruiting 
clinics serve large MSM populations; they undertake routine testing of MSM for rectal 
CT (using clinician or self-taken rectal swabs) regardless of symptoms and follow up 
some cases according to UK guidelines.[9] Specimens were submitted to the PHE 
Reference Laboratory for CT confirmation and LGV typing.[8] Residual CT-positive 
specimens were included in the GII study. 
 
Data collection 
Data on symptom presentation in study participants were systematically recorded by 
clinicians during the consultation and submitted to Public Health England (PHE) 
through a secure web-portal. The proforma covered CT- or LGV-related symptoms 
and included a free-text field to record non-specific symptoms (e.g. diarrhoea, loose 
stools).[8] Patients presenting with symptoms at any  attendance associated with a 
single STI care episode (typically 2-4 weeks duration) were defined as symptomatic. 
(In the original study only three patients were initially asymptomatic but subsequently 
symptomatic during the same care episode). Data on HIV status were available for 
patients in England (97%) from the national electronic STI surveillance system.[8,10] 
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Unlinked anonymous testing protocol 
As the GII testing protocol was not part of patients’ clinical care, to comply with the 
Data Protection Act, all residual specimens were irreversibly unlinked and 
anonymised prior to GII testing, a technique originally developed to monitor HIV 
prevalence.[11] A unique GII study number was assigned to each specimen and 
associated clinical data and a ‘GII study dataset’ created. Patient ID numbers in the 
GII study dataset were irreversibly deleted as were GII study numbers in all source 
datasets. Clinical data in the GII study dataset were restricted and summarised to 
prevent deductive disclosure of patients, into the following groups: (1) Region of 
residence (London/non-London), (2) Symptom status (symptomatic/asymptomatic), 
(3) HIV status (positive/negative), (4) LGV status (positive/negative). As only one 
patient presented with symptoms consistent with GII, GII symptoms were grouped 
with CT and LGV-related symptoms.  
 
DNA extraction and GII testing 
Residual rectal swabs which had been tested for CT/LGV as part of the LGV case-
finding study which had been stored at -20oC were used for GII testing. DNA was 
extracted using the QIAsymphony DSP DNA mini kit (Qiagen) according to 
manufacturer’s instructions.  Specimens were tested for Shigella sp., Campylobacter 
sp., Salmonella sp., shiga toxin-producing Escherichia coli (STEC) and 
enteroaggregative E. coli (EAEC) using a real-time PCR on a Rotorgene (Qiagen).  
The amplification parameters were 95oC for 5 minutes, followed by 95oC for 15 
seconds and 60oC for 60 seconds.  The cycle threshold was set at 0.05 for all 
targets.  Details of the primers, probes and gene targets are listed in the Web Table. 
 
Data analysis 
Summary clinical data were linked to the GII PCR test result using the GII study 
number.  We estimated GII prevalence with 95% confidence intervals (CI) and used 
Fisher’s exact tests to compare test results by patient characteristics, for each GII, 
and for all GII combined.  
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Ethical statement 
No individual patient consent was required or sought as PHE has authority to handle 
patient data for public health monitoring and infection control under section 251 of 
the UK National Health Service Act of 2006 (previously section 60 of the Health and 
Social Care Act of 2001).  
 
RESULTS 
Of 489 stored rectal specimens, 444 (91%) had DNA successfully extracted for PCR 
testing. Of these, 38 (8.5%) tested positive for any GII: 8 (1.8%) tested positive for 
Shigella sp., 8 (1.8%) for Campylobacter sp. and 23 (5.2%) for EAEC (Table). No 
specimens tested positive for Salmonella sp. or the other diarrhoeagenic E. coli 
pathotypes. One patient was co-infected with Shigella sp. and EAEC.  
Among those with GII, 30/38 were in London residents (8/8 with Shigella sp., 7/8 
Campylobacter sp. and 16/23 EAEC infections), 14/30 were asymptomatic (2/7 with 
Shigella sp., 3/6 with Campylobacter sp. and 9/17 with EAEC infections) and 16/30 
were HIV-positive (6/7 with Shigella sp., 4/6 with Campylobacter sp. and 6/17 with 
EAEC infections).  
GII prevalence was weakly associated with symptom presentation (13.1% in 
symptomatic versus 6.4% in asymptomatic; p=0.05) and in those who were HIV-
positive (12.6% in HIV-positive versus 6.3% in HIV-negative; p=0.05)(Table). The 
prevalence of Shigella sp. was significantly higher in MSM who were HIV-positive 
(4.7% versus 0.5% in HIV-negative MSM, p=0.01; Table).  
 
DISCUSSION 
To our knowledge, this is the first study to estimate GII prevalence in MSM with 
rectal CT attending STI clinics, much of which is likely to have been sexually 
transmitted. We show that 9% of MSM infected with rectal CT were co-infected with 
a GII; 13% if they were HIV-positive. Although not directly comparable, in a cohort of 
over 700 people attending UK general practice who developed GII symptoms, 
Shigella sp. was not detected and the detection rate of EAEC was lower, suggesting 
the burden of GII experienced by some MSM may be appreciable.[12] We have also 
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demonstrated the feasibility of using rectal swabs for GII testing. Rectal swabs are 
routinely taken for STI screening in sexual health clinics and might provide a 
practicable and acceptable method for investigating prevalence, clinical presentation 
and risk factors of GII in MSM to inform the public health response. Aside from 
bacterial GII, MSM have historically been at risk of various protozoan and viral GII, 
including Giardia spp., Entamoeba spp. and Hepatitis A.[13,14] We are exploring 
whether our approach can be used to identify a broader range of pathogens. 
Whether rectal swabs might replace faecal specimens for clinical diagnosis requires 
further investigation to validate test performance and determine whether swabs 
would facilitate organism culture for typing and antimicrobial resistance profiling. 
Even if feasible and acceptable, further research on the clinical and public health 
benefit is needed before introducing routine testing of asymptomatic MSM for GII in 
STI clinics.  
Use of a convenience sample to estimate GII prevalence introduces obvious 
limitations to our study. All men in the study had been diagnosed with rectal CT and 
do not represent MSM attending STI clinics overall, only those with a history of 
condomless receptive anal intercourse. Testing MSM with specific sexual risk 
behaviours has likely led to higher GII prevalence. Conversely, repeating DNA 
extraction from stored swabs for the GII study is likely to have reduced DNA quantity 
and quality and therefore test sensitivity, leading to under-estimation of GII 
prevalence. Furthermore, we had no information on specific practices associated 
with GII acquisition and the small sample size limited statistical power.  
Despite these limitations, the study provides important insights into GII epidemiology 
in MSM.  Although numbers were small, 14 of 30 MSM with GII were asymptomatic, 
suggesting asymptomatic carriage may play a role in infection transmission. Our 
findings further strengthen the association between Shigella sp. transmission and 
HIV-positive MSM, and suggest that a similar association may exist for 
Campylobacter sp.[5,7]  The factors underlying this relationship  may  be associated 
with HIV-sero-adaptive behaviours (choosing to have condomless sex with partners 
according to their perceived HIV status)  as has been observed in other STIs 
epidemics among MSM, and the effect of HIV infection on biological susceptibility 
and shedding of Shigella sp..[15,16]  
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The clinical and public health response to sexual transmission of Shigella spp. and 
other GII has been inadequate, partly because the role of asymptomatic and 
persistent infections in maintaining transmission remains unclear. This study 
contributes to our understanding of GII in MSM and demonstrates the potential value 
of using rectal swabs to detect GII in studies addressing these questions.    
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Table. Gastrointestinal infection (GII) PCR test results on rectal swabs taken from MSM diagnosed with rectal Chlamydia 
trachomatis at selected STI clinics in the UK: Prevalence with 95  confidence intervals (CI) and association with selected 
patient characteristics (N=444). 
  Shigella sp. Campylobacter sp. EAEC Any GII 
Variable** PCR-
+ve/ 
total 
tested 
(n/N) 
Prevalence (%) 
± 95% CI  
P 
value
* 
PCR-
+ve/ 
total 
tested 
(n/N) 
Prevalence (%) 
± 95% CI  
P 
value
* 
PCR-
+ve/ 
total 
tested 
(n/N) 
Prevalence (%) 
 ± 95 CI 
P 
value
* 
PCR-
+ve/ 
total 
tested 
(n/N) 
Prevalence (%) 
± 95 CI 
P 
value
* 
                     
Total 8/444 1.8 (0.9-3.6)  8/444 1.8 (0.9-3.6)  23/444 5.2 (3.5-7.7)  38/444 8.6 (6.3-11.6)  
                  
Region of UK 
residence 
 
0.21 
    
1.00 
    
0.30 
    
1.00 London 8/349 2.3 (1.2-4.5) 7/349 2.0 (1.0-4.2) 16/349 4.6 (2.9-7.4) 30/349 8.6 (6.1-12.1) 
Outside 
London 
0/95 0.0 (0.0-0.0) 1/95 1.1 (0.1-7.3) 7/95 7.4 (3.5-14.8) 8/95 8.4 (4.2-16.1) 
                  
Presence of 
symptoms 
 
0.10 
    
0.67 
    
0.31 
    
0.05 
Yes 5/122 4.1 (1.7-9.6) 3/122 2.5 (0.8-7.5) 8/122 6.6 (3.3-12.7) 16/122 13.1 (8.1-20.5) 
No 2/220 0.9 (0.2-3.6) 3/220 1.4 (0.4-4.2) 9/220 4.1 (2.1-7.7) 14/220 6.4 (3.8-10.4) 
                 
0.05 
HIV status  
0.01 
    
0.20 
    
1.00 
    
Positive 6/127 4.7 (2.1-10.2) 4/127 3.2 (1.2-8.2) 6/127 4.7 (2.1-10.2) 16/127 12.6 (7.8-19.7) 
Negative 1/222 0.5 (0.1-3.2) 2/222 0.9 (0.2-3.6) 11/222 5.0 (2.8-8.8) 14/222 6.3 (3.8-10.4) 
                 
LGV status  
0.58 
    
1.00 
    
0.72 
    
1.00 Positive 1/51 2.0 (0.3-13.4) 1/51 2.0 (0.3-13.4) 3/51 5.9 (1.8-17.3) 4/51 7.8 (2.9-19.7) 
Negative 5/332 1.5 (0.6-3.6) 7/332 2.1 (1.0-4.4) 15/332 4.5 (2.7-7.4) 27/332 8.1 (5.6-11.6) 
 
*Fisher’s Exact test. 
**Includes specimens with known variable information only. 
PCR-+ve = PCR test positive result 
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